# Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST)

> **NCT02260505** · PHASE3 · COMPLETED · sponsor: **Centre Leon Berard** · enrollment: 136 (actual)

## Conditions studied

- Gastrointestinal Stromal Tumors
- Resected Gastrointestinal Stromal Tumors
- Non-metastatic
- High Risk of Recurrence
- KIT Gene Mutation

## Interventions

- **DRUG:** Imatinib maintenance

## Key facts

- **NCT ID:** NCT02260505
- **Lead sponsor:** Centre Leon Berard
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12-24
- **Primary completion:** 2023-12
- **Final completion:** 2023-12
- **Target enrollment:** 136 (ACTUAL)
- **Last updated:** 2024-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02260505

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02260505, "Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02260505. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*